SCHEMBL20042575

SCHEMBL20042575

c1ccc(/N=C2/CCc3ccccc3N2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.48
▸ MAPK13 O15264 1/20 0.48
▸ MAPK12 P53778 1/20 0.48
▸ MAPK11 Q15759 1/20 0.48
▸ MAPK14 Q16539 1/20 0.48
▸ MAPT P10636 4/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ ATM Q13315 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ IDO1 P14902 1/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ AHR P35869 1/20 0.37
▸ PDK2 Q15119 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9372759 0.77 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL28118970 0.77 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL407439 0.75 NPC1 (0.70) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL3224077 0.74 ATM (0.48) NPC1MAPTMEN1KMT2AALDH1A1
SCHEMBL3224073 0.74 ATM (0.48) NPC1MAPTMEN1KMT2AALDH1A1
SCHEMBL15894024 0.74 NPC1 (0.44) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL1893352 0.69 ALDH1A1 (0.46) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL6469101 0.67 NPC1 (0.72) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL9551793 0.67 LRRK2 (0.50) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL4861947 0.66 MAPT (0.72) NPC1MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149399-A1 TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES USHER III INITIATIVE, INC. 2023-05-18 — — US disclosed
US-20230149399-A1 TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES USHER III INITIATIVE, INC. 2023-05-18 — — US disclosed
EP-3307742-B1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY USHER III INITIATIVE INC (US) 2022-05-18 — — EP disclosed
WO-2022011091-A1 TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES USHER III INITIATIVE, INC. (US) 2022-01-13 — — WO disclosed
US-20180099974-A1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY USHER III INITIATIVE, INC. 2018-04-12 — — US disclosed
US-20180099974-A1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY USHER III INITIATIVE, INC. 2018-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099974-A1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY PSMG3, HSPA5, TTR NPC1 964/4885MAPK13 3762/4885MAPK12 4088/4885
US-20230149399-A1 TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES TNF, HLA-DRB1, GSTK1 NPC1 1858/4885MAPK13 2590/4885MAPK12 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback